Blockchain Registration Transaction Record

New Drug Cuts Triglycerides 60%, Reduces Liver Fat in Trial

New medication DR10624 reduces triglycerides over 60% and cuts liver fat by 63% in clinical trial. First drug targeting FGF21, glucagon & GLP-1 receptors simultaneously for severe hypertriglyceridemia.

This development matters because severe hypertriglyceridemia affects millions worldwide and significantly increases the risk of life-threatening conditions including pancreatitis, heart attacks, and strokes. Current treatment options often provide inadequate results, leaving many patients with persistent health risks. The simultaneous reduction of both triglycerides and liver fat addresses two major metabolic health concerns that frequently coexist, potentially offering a more comprehensive treatment approach. For individuals struggling with difficult-to-manage lipid levels, this represents hope for better long-term health outcomes and reduced risk of serious complications. The multi-receptor targeting approach could also pave the way for more effective combination therapies for complex metabolic conditions that often cluster together, such as diabetes, obesity, and cardiovascular disease.